

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

NCI-H23

RRID:CVCL_1547

Type: Cell Line

Proper Citation

RRID:CVCL_1547

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1547

Proper Citation: RRID:CVCL_1547

Description: Cell line NCI-H23 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:1311061](#), [PMID:1565469](#), [PMID:1845952](#), [PMID:2041050](#), [PMID:2473086](#), [PMID:3335022](#), [PMID:3940644](#), [PMID:6148444](#), [PMID:6270685](#), [PMID:6272398](#), [PMID:7718330](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:9331090](#), [PMID:10358721](#), [PMID:10536175](#), [PMID:10700174](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:12820372](#), [PMID:15471562](#), [PMID:15748285](#), [PMID:15900046](#), [PMID:17088437](#), [PMID:19153074](#), [PMID:19372543](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:22961666](#), [PMID:23381221](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24135919](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25120651](#), [PMID:25485619](#), [PMID:25714623](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27602502](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:29681454](#), [PMID:29718670](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Karyotypic information: Has lost chromosome Y (PubMed=25714623)., Population: African American., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H23

Synonyms: NCI.H23, NCI H23, H-23, H23, NCIH23

Cross References: BTO:BTO_0003238, CLO:CLO_0008071, EFO:EFO_0002286, AddexBio:C0016005/4861, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5800, BioGRID_ORCS_Cell_line:526, BioSample:SAMN03471316, BioSample:SAMN03471735, BioSample:SAMN10988149, cancercellines:CVCL_1547, CCRID:3101HUMSCSP581, Cell_Model_Passport:SIDM00138, ChEMBL-Cells:ChEMBL3307750, ChEMBL-Targets:ChEMBL614997, CLS:305044, Cosmic:687818, Cosmic:722038, Cosmic:801587, Cosmic:844829, Cosmic:852004, Cosmic:875849, Cosmic:876142, Cosmic:877237, Cosmic:905942, Cosmic:910561, Cosmic:914948, Cosmic:917993, Cosmic:953983, Cosmic:961834, Cosmic:974292, Cosmic:1004697, Cosmic:1089217, Cosmic:1092619, Cosmic:1146906, Cosmic:1154591, Cosmic:1175864, Cosmic:1188590, Cosmic:1219060, Cosmic:1239881, Cosmic:1305347, Cosmic:1312332, Cosmic:1436010, Cosmic:1802313, Cosmic:1870271, Cosmic:1995567, Cosmic:1998461, Cosmic:2058647, Cosmic:2125183, Cosmic:2433751, Cosmic:2630416, Cosmic:2647631, Cosmic:2648436, Cosmic:2668310, Cosmic:2772151, Cosmic-CLP:905942, DepMap:ACH-000900, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905942, GEO:GSM2106, GEO:GSM50214, GEO:GSM50277, GEO:GSM171868, GEO:GSM171869, GEO:GSM206487, GEO:GSM253310, GEO:GSM274790, GEO:GSM274820, GEO:GSM353232, GEO:GSM385519, GEO:GSM385530, GEO:GSM434335, GEO:GSM482108, GEO:GSM513961, GEO:GSM514346, GEO:GSM743453, GEO:GSM750803, GEO:GSM794267, GEO:GSM799341, GEO:GSM799404, GEO:GSM817066, GEO:GSM827478, GEO:GSM844643, GEO:GSM847075, GEO:GSM887421, GEO:GSM888500, GEO:GSM1153412, GEO:GSM1178456, GEO:GSM1178457, GEO:GSM1181268, GEO:GSM1181312, GEO:GSM1374733, GEO:GSM1374734, GEO:GSM1374735, GEO:GSM1670229, GEO:GSM2124674, IARC_TP53:256, IGRhCellID:NCIH23, KCLB:90023, LiGeA:CCLE_892, LINCS_LDP:LCL-1619, NCI-DTP:NCI-H23, PharmacDB:NCIH23_1085_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1547, PubChem_Cell_line:CVCL_1547, SKY/M-FISH/CGH:2796, Wikidata:Q54907958

ID: CVCL_1547

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181244+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H23.

No alerts have been found for NCI-H23.

Data and Source Information

Usage and Citation Metrics

We found 370 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Li J, et al. (2026) Lactylation Enhances the Activity of Lactate Dehydrogenase A and Promotes the Chemoresistance to Cisplatin Through Facilitating DNA Nonhomologous End Junction in Lung Adenocarcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(3), e10733.

Chuikov S, et al. (2026) E2A selectively regulates TGF- β -induced apoptosis in KRAS-mutant non-small cell lung cancer. *Molecular oncology*, 20(7), 1877.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. *Journal of the National Cancer Center*, 6(3), 286.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. *Molecular oncology*.

Li Y, et al. (2026) Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation. *Cancer letters*, 640, 218241.

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. *International journal of molecular sciences*, 27(4).

Ge Y, et al. (2026) MTFR2 promotes VDAC1 oligomerization to reprogram BCAA metabolism in tumor cells to polarize TAMs in LUAD. *Cell death & disease*.

Meoni P, et al. (2026) Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors. *Molecular cancer therapeutics*, 25(3), 361.

Shang X, et al. (2026) Dual PD-1/IL-2R α targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. *Cell reports. Medicine*, 7(3), 102633.

Chen WT, et al. (2026) Functional genomic analysis reveals HAVCR1 as the key regulator of 5q33.3 locus linked to hyperlipidemia. *HGG advances*, 7(3), 100630.

Lu S, et al. (2025) Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. *Molecular cancer therapeutics*, 24(6), 920.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1069.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Daley BR, et al. (2025) SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. *Cancer research*, 85(1), 118.

Srivastava PP, et al. (2025) Epigenetic co-regulator HCF-1 promotes lung cancer via O-GlcNAcylation-dependent pathways. *Molecular therapy. Oncology*, 33(4), 201046.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. *Cancer research*, 85(22), 4380.

Aggarwal RK, et al. (2025) Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(4), 746.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. *Cancer research communications*, 5(2), 240.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.